LDL-c reductions below 1

Slides:

Advertisements

Similar presentations

Things we knew, things we did… Things we have learnt, things we should do LIPID MANAGEMENT IN PRIMARY CARE: HOW WELL DO WE DO? Dr. Carlos Brotons Research.

Advertisements

Flow chart showing number of citations retrieved by individual searches and number of trials included in review Strippoli GF, et al. BMJ 2008 Feb 25 [Epub.

Protecting the heart and the kidney: Implications from the SHARP trial Dr. Christina Reith University of Oxford United Kingdom.

New concepts and guidelines in the management of LDL-c and CV Risk: Need for early intervention Prof. Ulf Landmesser University Hospital Zürich Switzerland.

Weng TC, et al. J Clin Pharm Ther 2010;35:

VBWG IDEAL: The Incremental Decrease in End Points Through Aggressive Lipid Lowering Study.

Trial profile Prakash Deedwania, et al. Lancet 2006; 368:

Number of participants with diabetes by trial Cholesterol Treatment Trialists' (CTT) Collaborators Lancet 2008;371:

Baseline characteristics and eligibility criteria of participating trials Cholesterol Treatment Trialists’ (CTT) Collaborators Lancet 2005;366:

Double-blind, randomized trial in 4,162 patients with Acute Coronary Syndrome

Date of download: 6/29/2016 Copyright © The American College of Cardiology. All rights reserved. From: A Test in Context: High-Sensitivity C-Reactive Protein.

Date of download: 9/19/2016 Copyright © The American College of Cardiology. All rights reserved. From: Effect of Naturally Random Allocation to Lower Low-Density.

FOURIER Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk

NICE –CG 181 Continuum of CVD Risk and its treatment

Christie M. Ballantyne, MD

Reducing Adverse Outcomes after ACS in Patients with Diabetes Goals

Flow of Individuals Through the Vitamin E and Vitamin C Components of the Physicians’ Health Study II Howard D. Sesso et al. JAMA 2008;300:

LDL cholesterol in CKD—to treat or not to treat?

Predicted 5-year benefits of LDL cholesterol reductions with statin treatment at different levels of risk. (A) Major vascular events, and (B) vascular.

The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised.

Figure 1 Boxes represent effect estimates and lines represent 95% confidence intervals. (A) Effect of evolocumab on the risk of major vascular events [cardiovascular.

REVEAL: Randomized placebo-controlled trial of anacetrapib in 30,449 patients with atherosclerotic vascular disease Louise Bowman on behalf of the HPS.

Pravastatin in Elderly Individuals at Risk of Vascular Disease

Effects of Anacetrapib on the Incidence of New-Onset Diabetes Mellitus and on Vascular Events in People With Diabetes Louise Bowman & Martin Landray on.

Reduction in Total Cardiovascular Events with the PCSK9 Inhibitor Evolocumab in Patients with Cardiovascular Disease in the FOURIER Trial Sabina A. Murphy,

Copyright © 2002 American Medical Association. All rights reserved.

HDL cholesterol and cardiovascular risk Epidemiological evidence

APOC3 LOF heterozygotes have lower IVD and IHD risks due to lower RC

First time a CETP inhibitor shows reduction of serious CV events

Copyright © 2012 American Medical Association. All rights reserved.

SPIRE Program: Studies of PCSK9 Inhibition and the Reduction of Vascular Events Unanticipated attenuation of LDL-c lowering response to humanized PCSK9.

The Latest Lipid Guidelines:

HDL cholesterol and cardiovascular risk

AIM-HIGH Niacin Plus Statin to Prevent Vascular Events

What is the likely mechanism by which HDL-C reduces coronary heart disease?

Effects of High Density Lipoprotein Raising Therapies on Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus, with or without Renal Impairment:

Cholesteryl Ester Transfer Protein Inhibitors

Advances in Dyslipidemia: What Have We Learned From ACC 2017

LDL-C Goals. The Patient With Difficult-to-Treat Hypercholesterolemia: Is Everything Under Control?

An Update on PCSK9 Inhibitors

New Pathways in Lipid Care

Figure 1 Overview of lipoprotein metabolism and effects of novel lipid-modulating approaches Figure 1 | Overview of lipoprotein metabolism and effects.

PCSK9 Inhibitors and Cardiovascular Outcomes

Fellström BC, et al. N Engl J Med 2009;360:1455-7

The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised.

Updates in Cardiovascular Medicine

WHAT’S NEW WITH THE TREATMENTS FOR HIGH-RISK DYSLIPIDEMIA?

FOURIER Trial design: Patients with established cardiovascular disease on statin therapy were randomized to evolocumab 140 mg subcutaneous every 2 weeks.

I. Introduction American Journal of Kidney Diseases

To B or Not to B: Is Non–High-Density Lipoprotein Cholesterol an Adequate Surrogate for Apolipoprotein B? Carl J. Lavie, MD, Richard V. Milani, MD, James.

These slides highlight a presentation from a Special Session of the Late-Breaking Clinical Trials sessions during the American College of Cardiology 2005.

Reducing Risk for CV Outcomes

Potential mechanisms whereby statins may reduce the risk of stroke

LDL cholesterol in CKD—to treat or not to treat?

Lipid Updates From Spring 2019

Flow diagram for exclusions of trials identified RCT indicates randomized controlled trial Hulten E, et al. Arch Intern Med 2006;166:

An Update on PCSK9 Inhibitors

Cause of death Treatment-arm events, % (n=45 054)

Characteristics of Large Randomized Controlled Statin Trials Included in the Present Analysis Alawi A. et al. JACC 2008 Aug 20 [Epub ahead of print]

Relative Risk of Onset of Cancer from the Cholesterol Treatment Trialists’ (CTT) Meta-Analysis of Statin Trials, According to Year of Onset Risk ratios.

Titration activities from baseline up to 6 and 12 months follow-up in nurse-coordinated care (NCC) versus usual care patients. X-as: patients (percentage),

SPIRE Program: Studies of PCSK9 Inhibition and the Reduction of Vascular Events Unanticipated attenuation of LDL-c lowering response to humanized PCSK9.

TNT diabetes analysis: Baseline and final LDL cholesterol levels

T2DM patients with HF may benefit from SGLT2 inhibitor therapy

Additional benefit of PCSK9 inhibition in high risk patients after myocardial infarction A FOURIER subanalysis Primary endpoint: composite of CV death,

Increase of physical activity over time associated with lower HF risk

in diabetic patients with mixed dyslipidemia

Late-Breaking Data on LDL-C Reduction

The cumulative incidence curve demonstrated that patients with a sub-optimal LDL-C response to statin therapy were associated with a higher risk of CVD.

Medication intensity (ALLP) changes between baseline and 6 months, by (not) being low-density lipoprotein-cholesterol (LDL-C) target at baseline for nurse-coordinated.

Presentation transcript:

LDL-c reductions below 1 LDL-c reductions below 1.6 mmol/L provide additional vascular risk benefit A meta-analysis of CTTC, IMPROVE-IT, FOURIER, and REVEAL studies CTTC, IMPROVE-IT, FOURIER, REVEAL IMPROVE-IT, FOURIER, REVEAL CTTC LDL-c lowering better LDL-c lowering worse LDL-c: low density lipoprotein cholesterol; CTTC: Cholesterol Treatment Trialists Collaboration; IMPROVE-IT: Improved Reduction of Outcomes: Vytorin Efficacy International Trial; FOURIER: Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Patients With Elevated Risk; REVEAL: Randomized Evaluation of the Effects of Anacetrapib through Lipid Modification; HR: hazard ratio; LCL: lower confidence limit; UCL: upper confidence limit Sabatine et al. JAMA Cardiol 2018